Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Javed Butler, MD, MPH, MBA
Potassium Binders: Safety Comes First!
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
The Critical Interplay: CKD, HF, and Hyperkalemia
Javed Butler, MD
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Future Directions in Managing Hyperkalemia in CKD and HF
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
The Clinical Weight of TTR: What the Latest Data Reveal
Ahmad Masri, MD, MS
Rola Khedraki, MD
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Optimizing Barostim Outcomes: Practical Approaches to Patient Selection and Monitoring
Cynthia J. Bither, ACNP-BC, MSN
Andrea Wallace, MSN, FNP-C, HF-Cert
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA